As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
17 Analysts have issued a Immatics N.V forecast:
17 Analysts have issued a Immatics N.V forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 100 100 |
27%
27%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -153 -153 |
131%
131%
|
|
| EBIT (Operating Income) EBIT | -167 -167 |
112%
112%
|
|
| Net Profit | -136 -136 |
108%
108%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.
| Head office | Netherlands |
| CEO | Harpreet Singh-Jasuja |
| Employees | 646 |
| Founded | 2020 |
| Website | immatics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


